EU approves Roche's Avastin plus chemotherapy for women with advanced cervical cancer

Roche announced today that the European Commission (EU) approved Avastin (bevacizumab) in combination with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy) for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

Conclusion: Bimodal radiotherapy including IMRT and active raster-scanning CIRT for high-risk nasopharyngeal cancer is a safe treatment method resulting in moderate toxicity and excellent local control. A larger patient number and longer follow-up time would be necessary to strengthen the current findings.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: Available online 27 February 2019Source: International Journal of PharmaceuticsAuthor(s): Cenk Daglioglu, Fatma Necmiye KaciAbstractChemotherapy frequently involves combination treatment protocols to maximize tumor cell killing. Unfortunately these intensive chemotherapeutic regimes, often show disappointing results due to the development of drug resistance and higher nonspecific toxicity on normal tissues. In cancer treatment, it is critically important to minimize toxicity while preserving efficacy. We have previously addressed this issue and proposed a nanoparticle-based combination therapy involving b...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Abstract Currently cancer is the second leading cause of death globally and worldwide incidence and mortality rates of all cancers of males and females are rising tremendously. In spite of advances in chemotherapy and radiation, metastasis and recurrence are considered as the major causes of cancer related deaths. Hence there is a mounting need to develop new therapeutic modalities to treat metastasis and recurrence in cancers. A significant amount of substantiation from epidemiological, clinical and laboratory research highlights the importance of diet and nutrition in cancer chemoprevention. Enterolactone (EL) i...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   FIGO Stage IIB;   FIGO Stage IIIA;   FIGO Stage IIIB;   FIGO Stage IVA;   HIV Infection Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Paclitaxel;   Procedure: Patient Monitoring;   Radiation: Radiation Therapy Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (N...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: Patients with cervical SCC at stages IIb-IIIb, who received 4 cycles of chemotherapy using 50 mg/m2/week of cisplatin and EA at ST 36, had increased NK-cell percentages in their peripheral blood and had reductions in their cervical tumors. PMID: 30805077 [PubMed]
Source: Acupuncture in Medicine - Category: Complementary Medicine Authors: Tags: Med Acupunct Source Type: research
Conclusions: the results showed that the perimenopause age, low educational level, multiparity, cytopathologic result of HSIL and histopathological examination evidencing moderately differentiated squamous cell carcinoma were among the characteristics most related to cervical cancer in the population studied.Resumo Objetivos: avaliar o perfil sociodemogr áfico, clínico, histopatológico, citopatológico e microbiológico de mulheres com câncer de colo do útero atendidas em Centro de Oncologia Pernambucano. Métodos: estudo retrospectivo, que avaliou os prontuários d...
Source: Revista Brasileira de Saude Materno Infantil - Category: Midwifery Source Type: research
ConclusionDistant metastasis is the predominant pattern of failure for patients with SmCC treated with radical chemo-radiotherapy. With modern chemo-radiotherapy protocols we can expect a 5 year survival of around 50%. Early stage and (LN-) status appear to be favorable prognostic factors with survival rates at 5-year over 60%.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
ConclusionCCRT is a feasible therapeutic option with acceptable acute and chronic treatment-related toxicities for patients who cannot tolerate radical surgery or neoadjuvant chemotherapy.
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Chemotherapy | Pharmaceuticals | Women